Business
ENDRA Life Sciences Reports 2020 Fourth Quarter and Full Year Financial Results, Provides Business Update
Conference call begins at 4:30 p.m. Eastern time todayANN ARBOR, MI / ACCESSWIRE / March 25, 2021 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a
About this update from Endra Life Sciences Inc.
[{"type":"text","content":"Conference call begins at 4:30 p.m. Eastern time todayANN ARBOR, MI / ACCESSWIRE / March 25, 2021 / ENDRA Life Sciences Inc. (\"ENDRA\") (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and twelve months ended December 31, 2020 and provided a business update. Highlights of the fourth quarter of 2020 and recent weeks include the following:Partnered with Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical-stage biopharmaceutical company focused on AI-driven therapeutic drug development for the treatment of NASH and liver disease. ENDRA signed a collaboration agreement with Hepion to incorporate TAEUS as an add-on technology to support Hepion's patient screening and biomarker measurement during its upcoming Phase 2b study of CRV431.Secured a new clinical study partnership with Inselspital University Hospital in Bern, Switzerland. This is the third clinical research partnership for ENDRA in Europe and the sixth globally. The data from the Inselspital Bern study, along with other ongoing or to-be-initiated studies, will be used to bolster clinical evidence and further establish the clinical utility of the TAEUS device for assessing Non-Alcoholic Fatty Liver Disease (NAFLD).Began screening patients for real-world clinical validation. The first patient in a clinical study by an ENDRA clinical research partner took place at Rocky Vista University College of Osteopathic Medicine (\"RVUCOM\"). The TAEUS system was installed at RVUCOM's Ivins, Utah location in November 2020 with the first patient of a targeted 200, scanned in February 2021.Strengthened TAEUS intellectual property protection with issuance of two additional U.S. and one Chinese patents. ENDRA's intellectual property portfolio continues to grow and currently stands at 82 global assets, defined as patents issued, filed, licensed or in preparation. Extended collaboration agreement with GE Healthcare for two additional years. GE Healthcare will continue to support ENDRA's commercialization activities for its TAEUS technology for use in a fatty liver application by, among other things, facilitating introductions to GE Healthcare clinical ultrasound customers worldwide. Strengthened balance sheet with receipt of $18.5 million from the sale of common stock. As previously announced on December 18, 2020, the C...